AstraZeneca PLC (AZN)
67.87
+0.97
(+1.45%)
USD |
NASDAQ |
Apr 22, 16:00
68.90
+1.03
(+1.52%)
After-Hours: 07:43
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 210.42B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -1.25% |
| Valuation | |
| PE Ratio | 30.10 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.919 |
| Price to Book Value | 5.168 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.05 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.87% |
Profile
Edit
| A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales. |
| URL | https://www.astrazeneca.com |
| Investor Relations URL | https://www.astrazeneca.com/investor-relations.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Apr. 29, 2025 |
| Last Earnings Release | Feb. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 21, 2025 |
Ratings
Profile
Edit
| A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales. |
| URL | https://www.astrazeneca.com |
| Investor Relations URL | https://www.astrazeneca.com/investor-relations.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Apr. 29, 2025 |
| Last Earnings Release | Feb. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 21, 2025 |